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Abstract: A screening of Sudanese medicinal plants for antiprotozoal activities revealed that
the chloroform and water fractions of the ethanolic root extract of Haplophyllum tuberculatum
exhibited appreciable bioactivity against Leishmania donovani. The antileishmanial activity was
tracked by HPLC-based activity profiling, and eight compounds were isolated from the chloroform
fraction. These included lignans tetrahydrofuroguaiacin B (1), nectandrin B (2), furoguaiaoxidin
(7), and 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10), and four cinnamoylphenethyl amides,
namely dihydro-feruloyltyramine (5), (E)-N-feruloyltyramine (6), N,N′-diferuloylputrescine (8),
and 7′-ethoxy-feruloyltyramine (9). The water fraction yielded steroid saponins 11–13. Compounds
1, 2, and 5–13 are reported for the first time from Haplophyllum species and the family
Rutaceae. The antiprotozoal activity of the compounds plus two stereoisomeric tetrahydrofuran
lignans—fragransin B2 (3) and fragransin B1 (4)—was determined against Leishmania donovani
amastigotes, Plasmodium falciparum, and Trypanosoma brucei rhodesiense bloodstream forms, along with
their cytotoxicity to rat myoblast L6 cells. Nectandrin B (2) exhibited the highest activity against
L. donovani (IC50 4.5 µM) and the highest selectivity index (25.5).
Keywords: HPLC-Activity profiling; Leishmania; Plasmodium; Trypanosoma; Haplophyllum tuberculatum;
lignans; cinnamoylphenethyl amides; steroid saponins
1. Introduction
Neglected tropical diseases (NTDs) are a group of infectious diseases that are prevalent in
tropical and sub-tropical developing countries. NTDs are strongly associated with poverty, and of
high socio-economic impact. NTDs account for 48 million disability-adjusted life years (DALYs) and
152,000 deaths per year [1,2]. The NTD leishmaniasis, caused by Leishmania spp., imposes a global
burden of 3.3 million DALYS and 51,600 annual deaths [1,2]. There is no vaccine, and current drugs
are problematic given their serious adverse effects and the emergence of drug-resistant parasites [3].
There is one efficient and safe drug, AmBisome, a liposomal formulation of amphotericin B [4]. However,
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the high price of the drug and the need of an uninterrupted cold chain for delivery severely limits its
use. In Eastern Africa, a high-burden region of visceral leishmaniasis [5], sodium stibogluconate is still
the mainstay of leishmaniasis chemotherapy [3]. This pentavalent antimonial can cause hepatotoxicity
and cardiotoxicity [6]. Thus, there is an urgent need for the development of new, efficacious, safe,
and cost-effective drugs for the treatment of leishmaniasis and other diseases caused by kinetoplastid
parasites [7,8].
A library of Sudanese medicinal plants traditionally used as anti-infectives was screened for
antiprotozoal activity against Leishmania donovani, Trypanosoma brucei rhodesiense, Trypanosoma cruzi,
and Plasmodium falciparum. One of the most promising hits was Haplophyllum tuberculatum (Forssk.) A.
Juss. (Rutaceae). Chloroform and aqueous fractions obtained by partitioning of an ethanolic extract
from roots of the plant were active against L. donovani and P. falciparum (>85% growth inhibition at
10 µg/mL) [9].
Haplophyllum tuberculatum is a perennial herb distributed throughout North Africa and the
Middle East. In Sudan, the plant is locally known as Haza, and the aerial parts have been used
traditionally to treat malaria, asthma, kidney diseases, gynecological and bowel disorders [10,11].
Anti-inflammatory, antioxidant, antibacterial, and antifungal activities have been reported [10–12],
and alkaloids, flavonoids, coumarins and lignans have been identified [13–15]. The methanolic extract
of the aerial part and roots of H. tuberculatum possessed activity against P. falciparum [16], and Justicidin
A was found active [17]. The essential oil from the leaves had antileishmanial activity [18]. Justicidin B,
a lignan isolated from the leaves, showed trypanocidal activity [19].
The aim of this project was a systematic evaluation of the antiparasitic activities of H. tuberculatum
and the identification of the bioactive compounds by means of HPLC-based activity profiling.
2. Results and Discussion
2.1. Extraction and HPLC-based Activity Profiling
The chloroform and the water fractions from roots of H. tuberculatum had been previously found to
be active against L. donovani when tested at 10 µg/mL [9]. The antileishmanial activity was tracked by
HPLC-based activity profiling, a procedure combining time-based microfractionation with bioactivity
testing [20]. One-minute microfractions were collected and tested for growth inhibition of L. donovani
axenic amastigotes. The HPLC-ESIMS traces (base peak chromatograms in positive ion mode) overlaid
with the antileishmanial activity of microfractions are shown for the chloroform (Figure 1) and the
water fraction (Figure 2). Pronounced antileishmanial activity (>50% growth inhibition) was found
in the chloroform fraction in the time window of 16–21 min, and moderate activity (30–40% growth
inhibition) in the window of 12–15 min. For the water fraction, the antileishmanial activity was
confined to a narrow time window between 19–20 min.
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Figure 1. HPLC-based activity profiling of the chloroform fraction against axenic amastigotes of
L. donovani. The ESIMS (base peak chromatogram in positive ion mode) from a separation of 300 µg
of fraction is shown. For each microfraction the activity is expressed as percent growth inhibition in
comparison to untreated cultures (grey bars). Bold numbers in the chromatogram refer to compounds
1, 2, and 5–10.
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2.2. Compound Isolation and Structure l cidation
Preparative separation by MPLC of the chloroform fraction on a C18 cartridge yielded 13
subfractions (A-M). HPLC-PDA-MS analysis showed that subfractions B and C contained peaks from
the active time window. Further purification by semipreparative RP-HPLC afforded compounds
1 and 2 from subfraction B. Based on NMR data (Table S1, Supporting Information), the two
compounds were identified as the known lignans tetrahydrofuroguaiacin B (1) and nectandrin
B (2) (Figure 3) [21–23]. Semipreparative RP-HPLC of subfraction C afforded compounds 5–10.
By means of 1D a d 2D NMR dat (Tables S2 and S3, Supporting Information), these were id ntified as
four cinnamoylphenethyl amid s, namely dihydro-feruloylt ramine (5) [24], (E)-N-feruloyltyramine
(6) [25], N,N′-diferuloylputrescine (8) [26], and 7′-ethoxy-feruloyltyramine (9) [27], and two lignans,
furoguaiaoxidin (7) [23] and 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10) [28] (Figure 3). Compounds
9 and 10 showed optical rotation close to zero, and no cotton effects in the ECD spectra (Figures S1
and S2, Supporting Information). From a comparison with published data for the two compounds,
we conclude that they mostly likely were racemic mixtures.
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Preparative RP chromatography by MPLC of the water fraction on a C18 cartridge yielded 15
subfractions (A-O), whereby subfractions J and K contained the peaks from the active time window
of the activity profile (Figure 2). Semipreparative HPLC on a Hilic column afforded inseparable
mixtures of 11 and 12 from subfraction J, and 11 and 13 from subfraction K. The HRESIMS spectrum
of 11 exhibited a sodium adduct ion (m/z 1039.5083 [M + Na]+, calcd for C50H80O21Na+ 1039.5085)
indicative of a molecular formula of C50H80O21. The NMR data (Table S4, Supporting Information)
pointed to a steroidal saponin consisting of aglycon and four sugars. A comparison of 13C chemical
shifts with literature data identified the aglycon as yamogenin [29]. This was corroborated by a
detailed analysis of the 2D NMR spectra, in particular by cross peaks in the ROESY spectrum
between H-1β (δH 1.78), H3-19 (δH 0.94), H-8 (δH 1.54), H3-18 (δH 0.72), and H-20 (δH 1.75),
between H-1α (δH 0.96) and H-3 (δH 3.46), and between H3-21 (δH 0.92), H-17 (δH 1.65), H-16
(δH 4.27) and H-14 (δH 1.07). After hydrolysis and derivatization the sugars were identified as
d-glucose, l-rhamnose, and d-xylose [30]. The interglycosidic linkages and the attachment position
of the sugar chain at the aglycon were established by HMBC correlations (Figures S3 and S4,
Supporting Information) from δH 4.43 (1H, d, J = 7.5 Hz, H-1-Glc1) to δc 76.9 (C-3), from δH
5.04 (1H, br s, H-1-Rha1) to δc 76.4 (C-2-Glc1), from δH 4.34 (1H, d, J = 7.5 Hz, H-1-Glc2) to δc 81.1
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(C-4-Glc1), and from δH 4.38 (1H, d, J = 7.1 Hz, H-1-Xyl) to δc 86.4 (C-3-Glc2). saponin 11 was
identified as (3S,20S,22R,25S)-spirost-5-en-3-yl-(β-d-xylopyranosyl-(1→3)-β-d-glucopyranosyl-(1→4)
[α-l-rhamnopyranosyl-(1→2)]-β-d-glucopyranoside [31].
Compound 12 had a molecular formula of C51H82O21 (HRESIMS data m/z 1053.5233
[M + Na]+, calcd for C51H82O21Na+ 1053.5241). As for compound 11, NMR data (Table S4,
Supporting Information) indicated yamogenin bearing four sugars. The only difference
was in the presence of a rhamnopyranose instead of a xylopyranose (Figures S3 and
S4, Supporting Information). Thus, saponin 12 was identified as (3S,20S,22R,25S)-spirost-5-
en-3-yl-(β-d-rhamnopyranosyl-(1→3)-β-d-glucopyranosyl-(1→4)[α-l-rhamnopyranosyl-(1→2)]-β-
d-glucopyranoside [32]. Compound 13 had a molecular formula of C50H80O21 (m/z 1039.5072
[M + Na]+, calcd for C50H80O21Na+ 1039.5085). Based on the NMR data and especially
the carbon chemical shifts (Table S4, Supporting Information), the aglycone was identified
as diosgenin [29]. The sugar moiety was identical to that in saponin 11 (Figures S5 and
S6, Supporting Information). Compound 13 was therefore identified as (3S,20S,22R,25R)-
spirost-5-en-3-yl-(β-d-xylopyranosyl-(1→3)-β-d-glucopyranosyl-(1→4)[α-l-rhamnopyranosyl-(1→2)]-
β-d-glucopyranoside [31] (Figure 4). It is interesting to note that 11 and 13 are diastereoisomers with
the C-25 methyl group in axial or equatorial orientation, respectively.
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Figure 4. Chemical structures of (3S,20S,22R,25S)-spirost-5-en-3-yl-(β-d-xylopyranosyl-(1→3)-β-d-
glucopyranosyl-(1→4) [α-l-rhamnopyra s l-( )]-β-d-glucopyranoside (11), (3S,20S,22R,25S)-
spirost-5-en-3 yl-(β-d-rhamnopyra l )-β-d-glucopyranosyl-(1→4)[α-l-rhamnopyranosyl-
(1→2)]-β d glucopyranoside (12), and (3S,20S,22R,25R)-spirost-5-en-3-yl-(β-d- l 3)-β-
d-glucopyranosyl-(1→4)[α-l-rhamnopyranosyl-(1→2)]-β d-glucopyranoside (13).
2.3. Comparison to Previously Reported Compounds
The two tetrahydrofuran-type lignans 1 and 2 were previously reported from different
Myristicaceae, Elaeagnaceae, Poaceae, and Piperaceae species [22,33].
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Arylnaphthalen-type lignans had been identified in aerial part and roots of H. tuberculatum [34,35],
but tetrahydrofuran-type lignans are reported here for the first time from Haplophyllum species.
Cinnamoylphenethyl amides such as 5, 6, 8 and 9 have been reported from over 30 families
of flowering plants [36]. Amides 5 and 6 have been previously reported from different species of
Annonaceae [24,37,38] and Lauraceae [39,40]. Compound 6 was also found in Papaveraceae [41],
Cannabaceae [42], Solanaceae [25,43], and Portulacaceae [44,45], while 9 was identified in
Portulacaceae [44,45] and Cactaceae [27]. Amide 7 has been previously reported from Guaiacum
officinale [23], while compound 8 has been found in Tribulus terrestris [46], Peltophorum pterocarpum [47],
and Zea mays [48]. Amide 10 has been previously identified in Schisandra bicolor var. tuberculata [28].
Saponins 11–13 have been previously isolated, together with a series of similar
compounds, as molluscicidal saponins from the Sudanese medicinal plant Balanites aegyptiaca
(Zygophyllaceae) [31,32,49]. It can be assumed that saponins 11–13 contributed to the molluscicidal
activity that has been described for H. tuberculatum [50].
To the best of our knowledge, compounds 1, 2, and 5–13 have been isolated here for the first time
not only from Haplophyllum species but also from plants of the Rutaceae family.
2.4. Biological Testing
Compounds 1–10 were tested for their in vitro activities against the following protozoan parasites:
Leishmania donovani (MHOM/ET/67/L82) axenic amastigotes, Plasmodium falciparum (NF54) proliferative
erythrocytic stages, and Trypanosoma brucei rhodesiense (STIB 900) bloodstream forms (Table 1). In parallel,
cytotoxicity of these compounds in rat skeletal myoblasts (L-6 cells) was determined in order to obtain
an initial assessment of their selectivity. The results are reported in Table 1. Subfractions J and K
from the aqueous fraction containing steroidal saponins 11 and 12 in J, and 11 and 13 in K, exhibited
IC50 < 8 µg/mL across all parasites and a selectivity index <2, indicative of general cytotoxicity.
Table 1. In vitro Activity of compounds 1−10 against L. donovani (MHOM-ET-67/L82) axenic amastigotes,
P. falciparum (NF54), T. b. rhodesiense (STIB 900), and cytotoxicity in L6 Cells.
Compound L. donovani P. falciparum T. b. rhodesiense L6 Cells
No. IC50 a (µM) SI b IC50 a (µM) SI b IC50 a (µM) SI b
1 22.6 ± 6.5 4.2 53.1 ± 2.0 1.8 59.4 ± 2.5 1.6 95.2 ± 9.3
2 4.5 ± 1.0 25.5 9.5 ± 0.1 12.1 48.3 ± 1.3 2.4 115.0 ± 2.6
3 36.0 ± 7.3 4.7 36.1 ± 1.0 4.7 47.5 ± 4.5 3.6 2001 ± 47.0
4 29.2 ± 6.0 4.8 17.4 ± 2.1 8.0 40.7 ± 0.4 3.4 163.0 ± 4.5
5 141.3 ± 1.9 n.d 158.7 n.d 206.0 ± 66.7 n.d >317.5
6 99.4 ± 9.3 2.5 68.4 ± 3.8 3.6 120.9 ± 36.9 2.0 246.8 ± 3.7
7 136.5 ± 1.5 n.d 48.1 ± 10.9 n.d 114.0 ± 0.0 n.d >280.9
8 97.0 ± 0.9 1.5 30.6 ± 8.3 4.8 18.9 ± 8.4 7.8 146.5 ± 18.8
9 69.6 ± 4.6 3.0 30.4 ± 8.0 6.8 72.7 ± 30.4 2.9 207.8 ± 21.6
10 55.3 ± 3.0 2.3 9.3 ± 1.3 13.7 27.5 ± 8.4 4.6 127.6 ± 3.9
Positive control 0.5 d 0.01 e 0.01 c 0.03 f
a The IC50s are mean values from at least two independent replicates ± absolute deviation. b Selectivity index
(SI): IC50 in L6 cells divided by IC50 in the titled parasitic strain; c melarsoprol; d miltefosine; e chloroquine;
f podophyllotoxin; n.d: not determined.
2.4.1. Activity against Leishmania Donovani Axenic Amastigotes
Nectandrin B (2) was the most active (IC50 of 5 µM) and the most selective (SI 26) of all
compounds tested. This finding contrasts with a previous report on nectandrin B being inactive against
L. donovani [51]. The discrepancy may come from the fact that, in the aforementioned study, nectandrin
B was tested against the promastigote form of the parasite (i.e., the proliferative form in the gut of
the sandfly vector) while we tested against the amastigote form (i.e., the proliferative form in the
mammalian host). The antileishmanial activity cannot be ascribed to any particular mode of action
at this point. In general, some tetrahydrofuran lignans have been reported to inhibit trypanothione
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reductase [52], an enzyme of a thiol-redox system that is unique to trypanosomatid protozoa and
essential for their survival [53,54]. Compared to 2, tetrahydrofuroguaiacin B (1) was less active and
more toxic. The two compounds only differ in their stereochemistry at the tetrahydrofuran ring,
which therefore appears to play a crucial role in the antileishmanial activity of such lignans. To better
understand the role of the stereochemistry at the central ring and the contribution of substituents at the
aromatic rings, structurally related lignans 3 and 4 that had been previously reported from Myristica
fragrans Houtt. [21,22] were also included in the testing.
However, both compounds were significantly less active than nectrandrin B (2). Unfortunately,
the activity of nectandrin B (2) against L. donovani was lost in the intracellular amastigote assay tested
up to a concentration of 30 µM.
2.4.2. Activity against Plasmodium Falciparum
Lignans 2 and 10 were the most active and least toxic compounds (IC50 9–9.5 µM, SI 12–14).
Compound 10 was selectively active against P. falciparum. Compared to 2, fragransin B1 (4) (IC50 17 µM,
SI 8), was less active against P. falciparum, but was slightly more active and less cytotoxic than its
stereoisomer fragransin B2 (3). Amides 8 (IC50 30.6 µM, SI 4.8), and 9 (IC50 30.4 µM, SI 6.8) showed
comparable activity, while the congener 5 was the least active among all tested compounds.
A wide spectrum of biological activities of cinnamoylphenethyl amides has been described,
including antiproliferative [55], antibacterial [56], antifungal [57] and antioxidant activities [58]. To the
best of our knowledge, this is the first report of antileishmanial and antiplasmodial activities of
such compounds.
2.4.3. Activity against Trypanosoma Brucei Rhodesiense
Of all compounds tested, diferuloylputrescine (8) exhibited the highest activity against
T. b. rhodesiense and the highest selectivity (IC50 19 µM, SI 8). The lignan 10 showed a lower activity and
selectivity index (IC50 28 µM and SI 5), while 5 and 6 were the least active among all tested compounds.
None of the tetrahydrofuran lignans 1–4 exhibited significant activity against T. b. rhodesiense.
3. Materials and Methods
3.1. General Experimental Procedures
HPLC grade solvents from Sigma-Aldrich (St. Louis, MO, USA), and Macron Fine Chemicals
(Avantor Performance Materials, Phillipsburg, NJ, USA), and ultrapure water from a Milli-Q water
purification system (Merck Millipore, Darmstadt, Germany) were used for HPLC separations.
For extraction and preparative separation, technical grade solvents (Scharlab S. L., Barcelona, Spain)
were used after distillation. Silica gel 60 F254 coated aluminum TLC plates were obtained from Merck
(Darmstadt, Germany).
Optical rotation was measured in methanol on a JASCO P-2000 digital polarimeter (Tokyo, Japan)
equipped with a sodium lamp (589 nm) and a temperature-controlled microcell (10 cm). UV and
ECD spectra were recorded in methanol on a Chirascan CD spectrometer (Applied Photophysics,
Leatherhead, UK) using 110 QS 1 mm path precision cells (Hellma Analytics, Müllheim, Germany).
NMR spectra of compounds 1, 2, and 5–10 were recorded on a Bruker AVANCE III 500 MHz spectrometer
(Billerica, CA, USA) operating at 500.13 MHz for 1H and 125.77 MHz for 13C. 1H, COSY, HSQC, HMBC,
and NOESY spectra were measured at 23 ◦C in a 1-mm TXI probe with a z-gradient. The sample volume
was 10 µL. NMR spectra of 11–13 were recorded on a Bruker AVANCE NEO 600 MHz spectrometer
operating at 600.18 MHz for 1H and 150.92 MHz for 13C with an inverse 1.7 mm TCI micro-cryoprobe
(30 µL sample volume) at 23 ◦C. This cryogenically cooled probe delivered a 4-fold gain of mass
sensitivity over the 1 mm TXI room-temperature probe and enabled the NMR analysis of small sample
amounts (µg range), usually obtained for natural products. Spectra were analyzed by Bruker TopSpin
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3.5 pl 7 and ACDLabs Spectrus Processor. NMR spectra were recorded in DMSO-d6 99.9 atom%D
(Armar Chemicals, Döttingen, Switzerland).
HRESIMS data were measured in the positive ion mode on an Orbitrap LQT XL mass spectrometer
(Thermo Scientific, Waltham, MA, USA). HPLC-PDA-ELSD-ESIMS data were recorded in positive-
and negative-ion mode (scan range of m/z 200−1500) on a Shimadzu LC-MS/MS 8030 triple quadrupole
MS system (Kyoto, Japan) connected via a T-splitter (1:10) to a photo diode array detector (PDA)
(SPD-M20A, Shimadzu, Kyoto, Japan), and evaporative light scattering detector (ELSD) (3300, Alltech,
Büchi, Flawil, Switzerland). For data acquisition and processing, LabSolutions software (Kyoto, Japan)
was used.
Separations were performed on a C18 SunFire column (3.0 × 150 mm i. d., 3.5 µm) equipped with
a precolumn (10 × 3.0 mm i. d.) (Waters).
Microfractionation was carried out with the same HPLC instrument connected via a T split to
an FC204 fraction collector (Gilson, Mettmenstetten, Switzerland) with only UV detection, using a
SunFire C18 (3.5 µm, 150 × 3.0 mm i.d.) column equipped with a guard column (10 × 3.0 mm i.d.)
(Waters). Semipreparative HPLC were performed on an Agilent 1100 system (Santa Clara, CA, USA)
with PDA detector. A SunFire C18 column (5 µm, 10 × 150 mm i. d.) fitted with a guard column
(10 × 10 mm i.d.) (Waters) and a Nucleodur Hilic column (5 µm, 10 × 150 mm i. d.) (Macherey-Nagel),
were used for separations. ChemStation software (Agilent Technologies) was used for data acquisition
and processing. Preparative HPLC was carried out on a PuriFlash 4100 system (Interchim, Montluçon,
France). Separations were performed on RediSep Rf Gold ®-C18 MPLC cartridge 100g (Teledyne Isco).
3.2. Plant Material
Roots of Haplophyllum tuberculatum were collected in February 2018 in Khartoum, Sudan.
The taxonomic identity was confirmed by the Medicinal and Aromatic Plants Research Institute,
Sudan. A voucher specimen (HTR 02) is deposited at the Herbarium of the Faculty of Pharmacy,
University of Science and Technology, Omdurman, Sudan. The plant material was dried at room
temperature and milled with a hammer mill before extraction.
3.3. Extraction
The powdered roots of H. tuberculatum (300 g) were extracted with 1 L of 70% ethanol under stirring
for 24 h. The extract was filtered through Whatman no. 1 filter paper and concentrated in a rotary
evaporator to obtain 35.7 g of extract. The extract amount was suspended in water and partitioned
consecutively with petroleum ether, chloroform, and ethyl acetate. Three repetitive partitioning
procedures, each with 500 mL of either solvent, were performed. In total, 0.4 g of petroleum ether
fraction, 4.0 g of chloroform fraction, 2.0 g of ethyl acetate fraction, and 16.4 g of the water fraction
were obtained after evaporation.
3.4. Microfractionation for Activity Profiling
HPLC-based microfractionation of the chloroform and the water fractions was performed
[H2O + 0.1% formic acid (A), CH3CN + 0.1% formic acid (B); 0→100% B (0–30 min), 100% B (30–40 min);
flow rate 0.4 mL/min; sample concentration 10 mg/mL in DMSO; injection volume 2 × 35 µL] by
collecting one-minute fractions from minute 1 to 40 into a 96-deep-well plate. Plates were then dried in
a Genevac EZ-2 evaporator (Ipswich, UK) and prepared for antiprotozoal activity testing based on
previously established protocols [20,59].
3.5. Preparative Isolation
The chloroform fraction was reconstituted in DMSO and separated on a RediSep Rf Gold ® RP-C18,
100 gm cartridge [H2O (A), CH3CN (B); 5→100% B (0–120 min), flow rate 20 mL/min]. A total of
13 subfractions (A-M) were combined based on TLC patterns. The subfractions were analyzed by
HPLC-PDA-MS to track peaks previously detected in the active time windows of the activity profile.
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Subfraction B (247 mg) was submitted to semipreparative HPLC on a C18 column [H2O (A),
CH3CN (B); 56% B (0–35 min), 56→100% B (35–40 min), 100% B (40–45 min), flow rate 4 mL/min;
sample concentration 50 mg/mL in DMSO; injection volume 50 µL; detection at 208 nm] to afford
tetrahydrofuroguaiacin B (1, 2.2 mg, tR 22.3 min) and nectandrin B (2, 1.9 mg, tR 29.5 min).
A portion (200 mg) of subfraction C was separated by semipreparative HPLC on a C18 column
[H2O (A), MeOH (B); 39→48% B (0–30 min), 48→100% B (30–40 min), 100% B (40–45 min), flow rate
4 mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 µL; detection at 254
nm], and dihydro-feruloyltyramine (5, 2.5 mg, tR 9.4 min), (E)-N-feruloyltyramine (6, 10.6 mg,
tR 16.2 min), furoguaiaoxidin (7, 1.4 mg, tR 16.2 min), N,N′-diferuloylputrescine (8, 1.4 mg, tR 23.4 min),
7′-ethoxy-trans-feruloyltyramine (9, 1.1 mg, tR 27.3 min), and 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol
(10, 2.5 mg, tR 36.5 min) were obtained.
For the water fraction, an aliquot (8 g) was re-dissolved in water and separated by preparative
HPLC on a RediSep Rf Gold ® RP-C18, 100 gm cartridge [H2O (A), CH3CN (B); 20→65% B (0–120 min),
65→100% B (120–135 min), flow flow rate 20 mL/min]. Fractions with similar TLC patterns were
combined to yield 15 subfractions (A-O). HPLC-PDA-MS analysis located the peaks detected in the
active time window in subfractions J and K. Subfraction J (17 mg) was submitted to semipreparative
HPLC on a C18 column (H2O (A), CH3CN (B); 41% B (0–40 min), 41→100% B (40–45 min), 100% B
(45–50 min), flow rate 4 mL/min; sample concentration 50 mg/mL in DMSO; injection volume 50 µL;
detection at 193 nm) to afford compounds 11 and 12 as a mixture (2 mg, tR 22.3 min).
Subfraction K (53 mg) was submitted to semipreparative HPLC on a C18 column (H2O (A),
CH3CN (B); 40% B (0–40 min), 40→100% B (40–45 min), 100% B (45–50 min), flow rate 4 mL/min;
sample concentration 50 mg/mL in DMSO; injection volume 50 µL; detection at 193 nm), yielding
subfraction K3. Subfraction K3 (16 mg) was further purified by semipreparative HPLC on a Nucleodur
Hilic column (H2O (A), CH3CN (B); 92% B (0–35 min), 92→20% B (35–45 min), flow rate 4 mL/min;
sample concentration 50 mg/mL in DMSO; injection volume 50 µL; detection at 193 nm), to afford
compounds 11 and 13 as a mixture (4.2 mg, tR 25.2 min).
Tetrahydrofuroguaiacin (1): amorphous solid; [α]25D −1.9 (c 0.2, MeOH); 1H and 13C NMR,
see Table S1, Supporting Information; ESI-MS m/z 345 [M + H]+.
Nectandrin B (2): amorphous solid; [α]25D −1.2 (c 0.2, MeOH); 1H and 13C NMR, see Table S1,
Supporting Information; ESI-MS m/z 345 [M + H]+.
Fragransin B2 (3): amorphous solid; ESIMS m/z 405 [M + H]+.
Fragransin B1 (4): amorphous solid; ESIMS m/z 405 [M + H]+.
Dihydro-feruloyltyramine (5): amorphous solid; 1H and 13C NMR, see Table S2, Supporting
Information; ESIMS m/z 316 [M + H]+.
(E)-N-Feruloyltyramine (6): amorphous solid; 1H and 13C NMR, see Table S2, Supporting
Information; ESIMS m/z 314 [M + H]+.
Furoguaiaoxidin (7): amorphous solid; 1H and 13C NMR, see Table S2, Supporting Information;
ESIMS m/z 357 [M + H]+.
N,N′-Diferuloylputrescine (8): amorphous solid; 1H and 13C NMR, see Table S2, Supporting
Information; ESIMS m/z 441 [M + H]+.
7′-Ethoxy-trans-feruloyltyramine (9): amorphous solid; [α]25D −2.6 (c 0.11, MeOH); UV λmax (MeOH)
(log ε) 228 (0.23), 288 (0.12), 320 (0.11) nm; ECD (MeOH, c 2.0 × 10−4 M, 1 mm path length) λmax(∆ε) 207
(+4.04), 224 (+2.40), 235 (+1.72) nm; 1H and 13C NMR, see Table S3, Supporting Information; ESIMS
m/z 358 [M + H]+.
3,3′-Dimethoxy-4,4′-dihydroxylignan-9-ol (10): amorphous solid; [α]25D −4.9 (c 0.25, MeOH); UV
λmax (MeOH) (log ε) 230 (0.18), 280 (0.08) nm; ECD (MeOH, c 1.4 × 10−4 M, 1 mm path length) λmax(∆ε)
205 (+3.07), 215 (+1.39), 235 (+0.89) nm; 1H and 13C NMR, see Table S3, Supporting Information; ESIMS
m/z 693 [2M + H]+.
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(3S,20S,22R,25S)-Spirost-5-en-3-yl (β-d-xylopyranosyl-(1→3)- β-d-glucopyranosyl-(1→4)[α-l-
rhamnopyranosyl-(1→2)]-β-d-glucopyranoside (11): amorphous solid; 1H and 13C NMR, see Table S4,
Supporting Information; HRESIMS m/z 1039.5083 [M + Na]+ (calcd for C50H80O21Na+ 1039.5085).
(3S,20S,22R,25S)-Spirost-5-en-3-yl (β-d-rhamnopyranosyl-(1→3)- β-d-glucopyranosyl-(1→4)[α-l-
rhamnopyranosyl-(1→2)]-β-d-glucopyranoside (12): amorphous solid; 1H and 13C NMR, see Table S4,
Supporting Information; HRESIMS m/z 1053.5233 [M + Na]+ (calcd for C51H82O21Na+ 1053.5241).
(3S,20S,22R,25R)-Spirost-5-en-3-yl (β-d-xylopyranosyl-(1→3)-β-d-glucopyranosyl-(1→4)[α-l-
rhamnopyranosyl-(1→2)]-β-d-glucopyranoside (13): amorphous solid; 1H and 13C NMR, see Table S4,
Supporting Information; HRESIMS m/z 1039.5072 [M + Na]+ (calcd for C50H80O21Na+ 1039.5085).
3.6. Activity against Leishmania Donovani Axenic Amastigotes
Amastigotes of L. donovani strain MHOM/ET/67/L82 were grown under an atmosphere of 5% CO2 in
air in axenic culture at 37 ◦C in SM medium [60] at pH 5.4 supplemented with 10% heat-inactivated fetal
bovine serum. Next, 50 µL of culture medium was added in the wells of a 96-well plate and serial drug
dilutions of eleven 3-fold dilution steps covering a final range from 100 to 0.002 µg/mL were prepared.
Then, 50 µL of culture medium with 2 × 105 amastigotes from axenic culture were added to each well.
The plates were incubated for 70 h and then inspected under an inverted microscope to assure growth of
the controls and sterile conditions. 10 µL of resazurin (12.5 mg resazurin dissolved in 100 mL distilled
water) were added to each well of the plates and allowed for additional 2 h incubation. Afterwards,
plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation,
Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an emission wavelength of 588 nm.
Data were analyzed using the software Softmax Pro (Molecular Devices Cooperation, Sunnyvale,
CA, USA). Decrease of fluorescence (=inhibition) was expressed as percentage of the fluorescence of
untreated control cultures and plotted against the drug concentrations. From the sigmoidal inhibition
curves the IC50 values were calculated by linear regression using Microsoft Excel. Miltefosine was used
as positive control drug. Assays were performed in two independent replicates at least.
3.7. Activity against Leishmania Donovani Intramacrophage Amastigotes
Mouse peritoneal macrophages (4 × 104 in 100 µL RPMI 1640 medium with 10% heat-inactivated
FBS) were seeded into wells of a 96-well plate. After 24 h, 100 µL of 2 × 105 amastigote Leishmania
donovani were added. The amastigotes were taken from an axenic amastigote culture grown at pH 5.4.
The medium containing free amastigote forms was removed after 24 h and replaced with fresh medium.
The washing step was repeated and afterwards the serial drug dilution was prepared with at least
6 dilution steps. Compound was dissolved in DMSO at 10 mg/mL and further diluted in medium.
After incubation for 96 h at 37 ◦C under a 5% CO2 atmosphere, the medium was removed and cells were
fixed by adding 50 µL 4% formaldehyde solution followed by a staining with a 5 µM DRAQ5 solution.
Plates were imaged in ImageXpress XLS (MD) microscope using a 20× air objective (635 nm excitation:
690/50 emission). Nine images were collected per well. Automated image analysis was performed
with a script developed on Meta Xpress Software (MD). Three outputs were provided for each well:
(i) number of host cell nuclei; (ii) numbers of infected and non-infected host cells; (iii) number of
parasite nuclei per infected host cell. The IC50 values were calculated based on the infection rate and
the numbers of intracellular amastigotes. Miltefosine was used as control. Assays were performed in
two independent replicates at least.
3.8. Activity against Plasmodium Falciparum
In vitro activity against the erythrocytic stages of P. falciparum was determined using a
3H-hypoxanthine incorporation assay [61], using the drug-sensitive NF54 strain [62]. Compounds
were dissolved in DMSO at 10 mg/mL and further diluted in medium before addition to parasite
cultures incubated in RPMI 1640 medium without hypoxanthine, supplemented with HEPES (5.94 g/L),
NaHCO3 (2.1 g/L), neomycin (100 U/mL), AlbumaxR (5 g/L) and washed human red cells A+ at 2.5%
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haematocrit (0.3% parasitaemia). Serial drug dilutions of eleven 3-fold dilution steps covering a range
from 100 to 0.002 µg/mL were prepared. The 96-well plates were incubated in a humidified atmosphere
at 37 ◦C; 4% CO2, 3% O2, 93% N2. After 48 h 50 µL of 3H-hypoxanthine (=0.5 µCi) was added to each
well of the plate. The plates were incubated for a further 24 h under the same conditions. The plates
were then harvested with a Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red blood
cells transferred onto a glass fibre filter then lysed with distilled water. The dried filters were inserted
into a plastic foil with 10 mL of scintillation fluid, and counted in a Betaplate™ liquid scintillation
counter (Wallac, Zurich, Switzerland). IC50 values were calculated from sigmoidal inhibition curves
by linear regression using Microsoft Excel. Chloroquine (Sigma C6628) was used as positive control.
Assays were performed in two independent replicates at least.
3.9. Activity against Trypanosoma Brucei Rhodesiense
The stock was originally isolated from a Tanzanian patient and adapted to axenic culture conditions
after several mouse passages and cloned. Minimum Essential Medium (50 µL) supplemented with
25 mM HEPES, 1 g/L additional glucose, 1% MEM non-essential amino acids (100×), 0.2 mM
2-mercaptoethanol, 1mM Na-pyruvate [63] and 15% heat inactivated horse serum was added to each
well of a 96-well microtiter plate. Serial drug dilutions of eleven 3-fold dilution steps covering a range
from 100 to 0.002 µg/mL were prepared. Then 4 × 103 bloodstream forms of T. b. rhodesiense STIB
900 in 50 µL were added to each well and the plate incubated at 37 ◦C under a 5% CO2 atmosphere
for 70 h. 10 µL resazurin solution (resazurin, 12.5 mg in 100 mL double-distilled water) was then
added to each well and incubation continued for a further 2–4 h [64]. Then the plates were read with a
Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA)
using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analyzed
with the graphic programme Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA),
which calculated IC50 values by linear regression [65], and 4-parameter logistic regression from the
sigmoidal dose inhibition curves using Microsoft Excel. Melarsoprol (Arsobal Sanofi-Aventis, received
from WHO) was used as control. Assays were performed in two independent replicates at least.
3.10. In Vitro Cytotoxicity with L-6 Cells
Assays were performed in 96-well microtiter plates, each well containing 100 µL of RPMI 1640
medium supplemented with 1% l-glutamine (200 mM) and 10% fetal bovine serum, and 4000 L-6
cells (a primary cell line derived from rat skeletal myoblasts) [66]. Serial drug dilutions of eleven
3-fold dilution steps covering a range from 100 to 0.002 µg/mL were prepared 24 h post seeding L-6
cells. After 70 h of incubation the plates were inspected under an inverted microscope to assure
growth of the controls and sterile conditions. 10 µL of resazurin was then added to each well and the
plates incubated for another 2 h. Then the plates were read with a Spectramax Gemini XS microplate
fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of
536 nm and an emission wavelength of 588 nm. The IC50 values were calculated by linear regression
and 4-parameter logistic regression from the sigmoidal dose inhibition curves using SoftmaxPro
software (Molecular Devices Cooperation, Sunnyvale, CA, USA) and Microsoft Excel. Podophyllotoxin
(Sigma P4405) was used as control. All assays were performed in two independent replicates at least.
4. Conclusions
In total, eleven compounds (1, 2, and 5–13) have been reported here for the first time from
Haplophyllum species and the Rutaceae family. It is interesting to note that, to the best of our knowledge,
this is the first report on the presence of the saponin class in the respective plant species and family.
The antiprotozoal activity of these compounds, plus the two stereoisomeric tetrahydrofuran lignans
fragransin B2 (3) and fragransin B1 (4), was determined against L. donovani amastigotes, P. falciparum,
and T. b. rhodesiense bloodstream forms, along with their cytotoxicity to rat myoblast L6 cells. Nectandrin
B (2) exhibited the highest activity against L. donovani axenic amastigotes (IC50 4.5 µM) and the highest
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selectivity index (SI 25.5). The lignan 3,3′-dimethoxy-4,4′-dihydroxylignan-9-ol (10) was the most
active against P. falciparum (IC50 9.3 µM; SI 13.7). The steroidal saponins (11–13) showed activity with
IC50 < 8 µg/mL across all parasites; however, they were the least selective (SI < 2). The promising
activity of nectandrin B against axenic L. donovani amastigotes was not reproduced when tested against
intracellular amastigotes, possibly due to lack of penetration or stability of nectandrin B in macrophages.
Nevertheless, the specific antileishmanial activity of nectandrin B could serve as the starting point for
the identification of a new antileishmanial drug target.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/12/2825/s1,
Figure S1: UV (A) and ECD (B) spectra for compound 9 in MeOH (0.07 mg/mL), Figure S2: UV (A) and ECD (B)
spectra for compound 10 in MeOH (0.05 mg/mL), Figure S3: HSQC-DEPT spectrum of the mixture of compounds
11 (in red and black) and 12 (in blue and black) (500 MHz, DMSO), Figure S4: HMBC spectrum of the mixture
of compounds 11 and 12 (500 MHz, DMSO), Figure S5: HSQC-DEPT spectrum of the mixture of compounds 11
and 13 (labelled in red, a prime was added for signals differing from 11) (500 MHz, DMSO), Figure S6: HMBC
spectrum of the mixture of compounds 11 and 13 (500 MHz, DMSO), Table S1: 1H and 13C NMR Spectroscopic
Data for Compounds 1 and 2 (DMSO-d6; 500.13 MHz for 1H and 125.77 for 13C NMR; δ in ppm), Table S2: 1H and
13C NMR Spectroscopic Data for Compounds 5–8 (DMSO-d6; 500.13 MHz for 1H and 125.77 for 13C NMR; δ in
ppm), Table S3: 1H and 13C NMR Spectroscopic Data for Compounds 9 and 10 (DMSO-d6; 500.13 MHz for 1H and
125.77 for 13C NMR; δ in ppm), Table S4: 1H and 13C NMR Spectroscopic Data for Compounds 11–13 (DMSO-d6;
600.18 MHz for 1H and 125.77 for 13C NMR; δ in ppm).
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